IDH1 is altered in 7.58% of acute myeloid leukemia patients [3].

IDH1 is an inclusion criterion in 19 clinical trials for acute myeloid leukemia, of which 16 are open and 3 are closed. Of the trials that contain IDH1 status and acute myeloid leukemia as inclusion criteria, 6 are phase 1 (5 open), 7 are phase 1/phase 2 (6 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in acute myeloid leukemia [4].

IDH1 is altered in 15.57% of cholangiocarcinoma patients [3].

IDH1 is an inclusion criterion in 6 clinical trials for cholangiocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain IDH1 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in cholangiocarcinoma [4].

IDH1 is altered in 22.3% of chondrosarcoma patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for chondrosarcoma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and chondrosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in chondrosarcoma [4].

IDH1 is altered in 2.96% of malignant solid tumor patients [3].

IDH1 is an inclusion criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain IDH1 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [4].

IDH1 is altered in 24.88% of glioma patients [3].

IDH1 is an inclusion criterion in 13 clinical trials for glioma, of which 11 are open and 2 are closed. Of the trials that contain IDH1 status and glioma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 2 are no phase specified (2 open) [4].

IDH1 is altered in 2.52% of myelodysplastic syndromes patients [3].

IDH1 is an inclusion criterion in 9 clinical trials for myelodysplastic syndromes, of which 8 are open and 1 is closed. Of the trials that contain IDH1 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].

IDH1 is altered in 19.88% of malignant glioma patients [3].

IDH1 is an inclusion criterion in 5 clinical trials for malignant glioma, of which 5 are open and 0 are closed. Of the trials that contain IDH1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

IDH1 is altered in 68.64% of WHO grade II glioma patients [3].

IDH1 is an inclusion criterion in 4 clinical trials for WHO grade II glioma, of which 4 are open and 0 are closed. Of the trials that contain IDH1 status and WHO grade II glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

IDH1 is altered in 57.88% of anaplastic astrocytoma patients [3].

IDH1 is an inclusion criterion in 4 clinical trials for anaplastic astrocytoma, of which 3 are open and 1 is closed. Of the trials that contain IDH1 status and anaplastic astrocytoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 3 (1 open) [4].

IDH1 is altered in 81.17% of oligodendroglioma patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for oligodendroglioma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

IDH1 is altered in 41.98% of astrocytoma patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and astrocytoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

IDH1 is altered in 1.38% of myeloproliferative neoplasm patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for myeloproliferative neoplasm, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

IDH1 is altered in 0.57% of lymphoma patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IDH1 status and lymphoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

IDH1 is altered in 0.45% of breast carcinoma patients [3].

IDH1 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain IDH1 status and breast carcinoma as inclusion criteria, 2 are phase 1 (0 open) and 1 is phase 2 (1 open) [4].

IDH1 is altered in 59.78% of diffuse astrocytoma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for diffuse astrocytoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and diffuse astrocytoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

IDH1 is altered in 59.02% of WHO grade III glioma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for WHO grade III glioma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].

IDH1 is altered in 9.61% of glioblastoma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) [4].

IDH1 is altered in 3.5% of hematopoietic and lymphoid malignancy patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for hematopoietic and lymphoid malignancy, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 2 are phase 1 (2 open) [4].

IDH1 is altered in 1.6% of myelodysplastic syndrome with excess blasts-2 patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 2 are phase 2 (1 open) [4].

IDH1 is altered in 1.02% of chronic myelomonocytic leukemia patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

IDH1 is altered in 0.89% of non-small cell lung carcinoma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain IDH1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (0 open) [4].

IDH1 is altered in 0.48% of pancreatic carcinoma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

IDH1 is altered in 0.36% of ovarian carcinoma patients [3].

IDH1 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain IDH1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

IDH1 is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

IDH1 is altered in 85.53% of mixed glioma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for mixed glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and mixed glioma as inclusion criteria, 1 is phase 3 (1 open) [4].

IDH1 is altered in 82.22% of anaplastic oligodendroglioma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 82.14% of oligoastrocytoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and oligoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 49.63% of low grade glioma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and low grade glioma as inclusion criteria, 1 is phase 3 (1 open) [4].

IDH1 is altered in 26.4% of diffuse glioma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 25.0% of atypical chronic myeloid leukemia, BCR-ABL1 negative patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 22.64% of intrahepatic cholangiocarcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IDH1 is altered in 17.82% of high-grade glioma, NOS patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 15.57% of bile duct carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and bile duct carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IDH1 is altered in 9.52% of malignant hepatobiliary neoplasm patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IDH1 is altered in 7.23% of secondary acute myeloid leukemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 7.23% of therapy-related acute myeloid leukemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 6.9% of myeloproliferative neoplasm, unclassifiable patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 6.62% of leukemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 4.65% of myeloid neoplasm patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 3.01% of melanoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 2.99% of cancer patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 2.33% of acute promyelocytic leukemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 2.2% of medulloblastoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.98% of central nervous system embryonal neoplasm patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.84% of essential thrombocythemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.82% of primary brain neoplasm patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and primary brain neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.77% of primary myelofibrosis patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for primary myelofibrosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and primary myelofibrosis as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.69% of chronic myeloid leukemia patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 1.51% of myelofibrosis patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH1 is altered in 1.45% of schwannoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 1.39% of bladder carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 1.3% of colorectal carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 1.32% of sarcoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 1.41% of gallbladder carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH1 is altered in 1.01% of myelodysplastic/myeloproliferative neoplasm patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is altered in 0.64% of prostate carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 0.52% of head and neck carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 0.47% of hepatocellular carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

IDH1 is altered in 0.66% of gastric carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is altered in 0.4% of multiple myeloma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH1 is altered in 0.21% of gastrointestinal stromal tumor patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 0.39% of pleural mesothelioma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 0.2% of renal cell carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is altered in 0.13% of clear cell renal cell carcinoma patients [3].

IDH1 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and meningioma as inclusion criteria, 1 is phase 2 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and polycythemia vera as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 1 (1 open) [4].

IDH1 is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].